USANA HEALTH SCIENCES INC (USNA)
US90328M1071 - Common Stock
Taking everything into account, USNA scores 6 out of 10 in our fundamental rating. USNA was compared to 37 industry peers in the Personal Care Products industry. USNA has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. USNA is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
USNA had positive earnings in the past year.
USNA had a positive operating cash flow in the past year.
In the past 5 years USNA has always been profitable.
USNA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 10.08%, USNA belongs to the best of the industry, outperforming 81.08% of the companies in the same industry.
USNA has a better Return On Equity (12.82%) than 75.68% of its industry peers.
Looking at the Return On Invested Capital, with a value of 11.41%, USNA is in the better half of the industry, outperforming 72.97% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for USNA is above the industry average of 13.69%.
The 3 year average ROIC (17.38%) for USNA is well above the current ROIC(11.41%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.08% | ||
| ROE | 12.82% | ||
| ROIC | 11.41% |
ROA(3y)13.96%
ROA(5y)16.16%
ROE(3y)19.43%
ROE(5y)23.02%
ROIC(3y)17.38%
ROIC(5y)19.97%
1.3 Margins
The Profit Margin of USNA (6.92%) is better than 67.57% of its industry peers.
USNA's Profit Margin has declined in the last couple of years.
USNA's Operating Margin of 10.10% is fine compared to the rest of the industry. USNA outperforms 67.57% of its industry peers.
USNA's Operating Margin has declined in the last couple of years.
USNA has a better Gross Margin (80.80%) than 100.00% of its industry peers.
USNA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.1% | ||
| PM (TTM) | 6.92% | ||
| GM | 80.8% |
OM growth 3Y-13.39%
OM growth 5Y-8.6%
PM growth 3Y-14.27%
PM growth 5Y-8.18%
GM growth 3Y-0.31%
GM growth 5Y-0.56%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so USNA is creating value.
Compared to 1 year ago, USNA has less shares outstanding
The number of shares outstanding for USNA has been reduced compared to 5 years ago.
USNA has a worse debt/assets ratio than last year.
2.2 Solvency
USNA has an Altman-Z score of 7.62. This indicates that USNA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of USNA (7.62) is better than 86.49% of its industry peers.
There is no outstanding debt for USNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.01 | ||
| Altman-Z | 7.62 |
ROIC/WACC1.26
WACC9.02%
2.3 Liquidity
A Current Ratio of 3.52 indicates that USNA has no problem at all paying its short term obligations.
USNA's Current ratio of 3.52 is fine compared to the rest of the industry. USNA outperforms 75.68% of its industry peers.
USNA has a Quick Ratio of 3.00. This indicates that USNA is financially healthy and has no problem in meeting its short term obligations.
USNA's Quick ratio of 3.00 is fine compared to the rest of the industry. USNA outperforms 75.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.52 | ||
| Quick Ratio | 3 |
3. Growth
3.1 Past
USNA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.31%.
Measured over the past years, USNA shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.37% on average per year.
USNA shows a decrease in Revenue. In the last year, the revenue decreased by -7.57%.
The Revenue has been decreasing by -4.98% on average over the past years.
EPS 1Y (TTM)-5.31%
EPS 3Y-17.42%
EPS 5Y-8.37%
EPS growth Q2Q-9.47%
Revenue 1Y (TTM)-7.57%
Revenue growth 3Y-6.72%
Revenue growth 5Y-4.98%
Revenue growth Q2Q-8.29%
3.2 Future
Based on estimates for the next years, USNA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.32% on average per year.
USNA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.81% yearly.
EPS Next Y-15.76%
EPS Next 2Y-1.7%
EPS Next 3Y19.32%
EPS Next 5YN/A
Revenue Next Year-2.5%
Revenue Next 2Y0.46%
Revenue Next 3Y7.81%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 15.26, USNA is valued correctly.
Based on the Price/Earnings ratio, USNA is valued cheaply inside the industry as 83.78% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 28.15, USNA is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 15.36, the valuation of USNA can be described as correct.
Compared to the rest of the industry, the Price/Forward Earnings ratio of USNA indicates a rather cheap valuation: USNA is cheaper than 83.78% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.20, USNA is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.26 | ||
| Fwd PE | 15.36 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of USNA indicates a rather cheap valuation: USNA is cheaper than 97.30% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of USNA indicates a somewhat cheap valuation: USNA is cheaper than 67.57% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.79 | ||
| EV/EBITDA | 5.71 |
4.3 Compensation for Growth
USNA has a very decent profitability rating, which may justify a higher PE ratio.
USNA's earnings are expected to grow with 19.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.7%
EPS Next 3Y19.32%
5. Dividend
5.1 Amount
USNA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
USANA HEALTH SCIENCES INC
NYSE:USNA (5/17/2024, 7:04:00 PM)
After market: 48.99 0 (0%)48.99
+0.47 (+0.97%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap942.57M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.26 | ||
| Fwd PE | 15.36 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.08% | ||
| ROE | 12.82% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 10.1% | ||
| PM (TTM) | 6.92% | ||
| GM | 80.8% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.52 | ||
| Quick Ratio | 3 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-5.31%
EPS 3Y-17.42%
EPS 5Y
EPS growth Q2Q
EPS Next Y-15.76%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-7.57%
Revenue growth 3Y-6.72%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y